Technology

Instem plc

Market Cap (£m) 168.9
Listing AIM

Company Description

Instem is a leading provider of IT solutions & services to the life sciences market. Instem's software enables its customers (mainly pharmaceutical companies) to bring their life-enhancing drugs to market faster.

Investment Summary

Instem came to market in 2010 with a compelling story based on dominance of a niche market, good recurring revenues and strong cash generation. In our view, the group has a strong track record of delivery, and the favourable market backdrop gives further confidence in the growth story.

Recent Content

More Content

Company Management Team

  • Phil Reason

    Chief Executive Officer

    Phil has been leading Instem as CEO since 1995, working closely with the Instem Board, investors, management, clients, partners and staff to grow the business from a single product line with fifteen clients to serving hundreds of customers as the global market leader across a wide area of life sciences R&D.  Passionate about Instem’s ability to support clients in introducing transformational approaches for life changing therapies, Phil has been a vocal advocate of long-term partnerships, innovative organic growth, geographic expansion and the acquisitive consolidation of the fragmented IT supplier community. Under Phil’s leadership Instem has completed the strategic acquisition of 7 companies, has opened new offices in the US, UK, China, and India and has completed a UK-based IPO in 2010.

  • Nigel Goldsmith

    Chief Financial Officer

    Nigel joined Instem in November of 2011 and possesses a wealth of experience in senior financial roles at both public and private companies within the life sciences industry. Prior to Instem, Nigel was Finance Director for 3 years at the AIM listed, pharmaceutical and medical devices company, IS Pharma plc. He also held the position of CFO for 7 years at Almedica International Inc., a privately held supplier of clinical trial materials to the global pharmaceutical and biotech markets and 2 years as European Controller for the sales and marketing division of laboratory equipment manufacturer, Life Sciences International plc. Prior to entering industry, Nigel spent over 9 years at KPMG and is a qualified Chartered Accountant.

Key Dates

Jul 2019
15th
Q2 TU
Actual
Sep 2019
23rd
Interims
Actual
Jan 2020
13th
Q4 TU
Actual
Jun 2020
3rd
Finals
Actual
Jun 2020
30th
AGM
Actual
Jul 2020
20th
Q2 TU
Actual
Jul 2020
23rd
CMD
Actual
Sep 2020
28th
Interims
Actual
Jan 2021
14th
Q4 TU
Actual
Apr 2021
12th
Finals
Actual
May 2021
27th
AGM
Actual
Jul 2021
1st
CMD
Actual
Jul 2021
19th
Q2 TU
Actual
Sep 2021
27th
Interims
Actual
Jan 2022
26th
Q4 TU
Actual
Apr 2022
26th
Finals
Actual
Jun 2022
9th
AGM
Actual
Jul 2022
19th
Q2 TU
Estimate
Sep 2022
27th
Interims
Estimate
Jan 2023
26th
Q4 TU
Estimate
Apr 2023
26th
Finals
Estimate
Jun 2023
9th
AGM
Estimate